Soleus Capital Management’s AstraZeneca AZN Stock Holding History

Soleus Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-204,500	Closed	-$26.8M	–	77
2024 Q4	$26.8M	Buy	+204,500	New	+$28.6M	1.68%	19
2022 Q3	–	Sell	-84,848	Closed	-$11.2M	–	78
2022 Q2	$11.2M	Buy	84,848 +28,500	+51%	+$3.74M	1.75%	20
2022 Q1	$7.48M	Sell	56,348 -182,950	-76%	-$21.9M	0.96%	35
2021 Q4	$27.9M	Buy	239,298 +79,600	+50%	+$9.37M	2.79%	7
2021 Q3	$19.2M	Buy	159,698 +34,625	+28%	+$4.03M	2.99%	9
2021 Q2	$15M	Sell	125,073 -4,150	-3%	-$455K	2.3%	14
2021 Q1	$12.8M	Buy	129,223 +97,081	+302%	+$9.76M	2.32%	8
2020 Q4	$3.21M	Buy	32,142 +27,540	+598%	+$2.92M	0.42%	26
2020 Q3	$504K	Sell	4,602 -63,505	-93%	-$7.06M	0.27%	55
2020 Q2	$7.2M	Buy	+68,107	New	+$7.03M	4.11%	5

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Soleus Capital Management's AZN Position: Q1 2025 in Review

Soleus Capital Management sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 204,500 shares — an estimated $26.8M sold.

Soleus Capital Management first reported a position in AZN in Q2 2020 and held it in 10 quarters. The position peaked at $27.9M in Q4 2021. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

Soleus Capital Management reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
Soleus Capital Management sold 204,500 AstraZeneca shares in Q1 2025, an estimated $26.8M.
Soleus Capital Management first reported a position in AstraZeneca in Q2 2020 and held it in 10 quarters.
Soleus Capital Management's AstraZeneca position peaked at $27.9M in Q4 2021.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.